Koninklijke Philips NV Q3 FY2024 earnings call

Key financial highlights: Group comparable sales flat, orders down 2%, adjusted EBITA margin up 160 basis points, free cash flow EUR22M. China focus: Personal Health in China saw double-digit decline in consumer sell-out; hospitals affected by anticorruption measures and lack of national renewal program impact. Innovation milestones: U.S. grilling clinic expansion, FDA clearances for cardiovascular ultrasound and LumiGuide navigation wire, AI-powered baby monitor launch. Execution priorities: Patient safety culture strengthening, supply chain lead times back to normal, simplified operating model with over EUR1.5 billion productivity gains.

Diagnosis & Treatment comparable sales decreased 1% on back of 14% growth in Q3 2023; adjusted EBITDA margin 12.6% in line with last year. Connected Care comparable sales flat; adjusted EBITDA margin increased 360 basis points to 7.3%. Personal Health comparable sales decreased 5% due to double-digit decline in China; adjusted EBITDA margin 16.5% year-on-year decrease but up over 100 basis points year-to-date. Segment Other sales EUR41M higher than Q3 2023 due to royalty revenues.

Full year group comparable sales guidance revised to 0.5%-1.5% growth; outside China 3%-5% growth. Adjusted EBITDA margin expected around 11.5% (upper end of range). Free cash flow expected around EUR-0.9 billion (lower end of range).

Continued uncertainty in China market, impact of anticorruption measures and delayed government programs. Supply chain and regulatory risks, including ongoing FDA engagements and potential tariffs.

Q: On hospital equipment business in China, extent of weakness due to market vs Philips-specific issues?

A: Market development with prolonged uncertainty, orders not flowing into market, visibility low but order funnel active.

Q: On gross margin improvement, quantify drivers and durability?

A: Driven by strong gross margins from innovations, operational improvements, and financial discipline; seen as durable with continued innovation and productivity efforts.

Q: On China orders deterioration, quantum vs Q2, base case for Q4?

A: China orders saw significant deterioration, with hospital and consumer sides affected; base case for Q4 uncertain but order funnel active with low visibility.

Q: On pricing trends over 1-2 years?

A: Saw pricing benefit in Q3, remains fluid; focus on material price reductions and competitive stance.

Q: On China market outlook and growth post-recovery?

A: China remains attractive but visibility limited; growth expected outside China in segments like IGT, Personal Health outside China, etc.